ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer

Background Docetaxel and prednisolone chemotherapy (DP) extends survival in metastatic castration resistant prostate cancer (mCRPC). However, emergent clinical resistance is almost inevitable. AKT pathway activation is highly prevalent in mCRPC contributing to disease progression and DP resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Crabb, Simon J., Birtle, Alison J., Martin, Karen, Downs, Nichola, Ratcliffe, Ian, Maishman, Tom, Ellis, Mary, Griffiths, Gareth, Thompson, Stuart, Ksiazek, Lidia, Khoo, Vincent, Jones, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613074/
https://www.ncbi.nlm.nih.gov/pubmed/28144789
http://dx.doi.org/10.1007/s10637-017-0433-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613074/
https://www.ncbi.nlm.nih.gov/pubmed/28144789
http://dx.doi.org/10.1007/s10637-017-0433-4

Ejemplares similares